Latest on NET.  Camurus announces completed enrolment in the Phase 3 SORENTO study of CAM2029 in patients with neuroendocrine tumours December 14, 2023 at 02:01 am EST Lund, Sweden – 14 December 2023 – Camurus (NASDAQ STO: CAMX) today announces completed enrolment in the randomized, active-controlled Phase 3 SORENTO study evaluating the efficacy and safety of octreotide subcutaneous depot … Continue reading A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With GEP-NET (SORENTO)